Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Hodgkin Disease 80Lymphoma 35Lymphoma, Large-Cell, Anaplastic 26Hematologic Diseases 21Recurrence 18Lymphoma, Non-Hodgkin 17Lymphoma, T-Cell, Peripheral 14Lymphoma, T-Cell, Cutaneous 13Lymphoma, T-Cell 13Lymphoma, Large B-Cell, Diffuse 10Mycosis Fungoides 9Sezary Syndrome 5Neoplasms 5Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphomatoid Papulosis 4Lymphoma, Primary Cutaneous Anaplastic Large Cell 4Lymphatic Diseases 4Leukemia, Myeloid, Acute 4Immunoblastic Lymphadenopathy 4Enteropathy-Associated T-Cell Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Lymphoma, Follicular 3Leukemia 3Dendritic Cell Sarcoma, Interdigitating 3Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2

Interventions

Vincristine 3Prednisone 3Doxorubicin 3Cyclophosphamide 3pembrolizumab 2Vorinostat 2Etoposide 2Bortezomib 2siplizumab 1prednylidene 1pirarubicin 1liposomal doxorubicin 1etoposide phosphate 1Salvia hispanica seed extract 1Rituximab 1Methotrexate 1Ifosfamide 1Everolimus 1Cholecalciferol 1Brentuximab Vedotin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Subcutaneous panniculitis-like T-cell lymphoma × Brentuximab Vedotin × Clear all
NCT04795869 2023-10-10

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Northwestern University

Phase 2 Withdrawn
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡